# PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria

> **NCT03168295** · PHASE4 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 34 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Dapagliflozin 10mg then Placebo Oral Tablet
- **DRUG:** Placebo Oral Tablet then Dapagliflozin 10mg

## Key facts

- **NCT ID:** NCT03168295
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2018-10
- **Final completion:** 2019-05-15
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2020-09-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03168295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03168295, "PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03168295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*